BIGNON LEBRAY advises Vaxinano with regard to its raising of capital
BIGNON LEBRAY has advised Vaxinano, a biotech company specializing in the development of new vaccines for the treatment of viral, bacterial or parasitic infections in the fields of human and animal health.
Created in July 2016, Vaxinano, a biotech company raised € 400K in two months from Business Angels and is expected to complete the transaction with € 850K by the end of 2017.
Using nanoparticles as a delivery vector, Vaxinano offers, nasal-administered vaccines with unrivaled performance that are free of adjuvant and 100% bioeliminable.
This raising of capital will allow to finance the R & D efforts estimated at 1.25 M € for the next two years.
Vaxinano was advised by Thomas Buffin, a partner at BIGNON LEBRAY law firm, Head of the Mergers and Acquisitions department of the Lille office. He advises and assists his clients (start-up, JEI, SME, gazelle, ETI, unicorn) in all their undertakings, i.e. acquisition, sale, asset transfer, merger, tax optimization, transformation, restructuring, and is particularly active in the areas of innovation, health, and new technologies.